Home > Journals > Italian Journal of Dermatology and Venereology > Past Issues > Articles online first > Italian Journal of Dermatology and Venereology 2021 Apr 21

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

 

Italian Journal of Dermatology and Venereology 2021 Apr 21

DOI: 10.23736/S2784-8671.21.06915-7

Copyright © 2021 EDIZIONI MINERVA MEDICA

language: English

A new combination of molecules for the treatment of androgenetic alopecia and telogen effluvium: a double-blind randomized, monocentric, placebo-controlled study

Alfredo ROSSI 1 , Francesca MAGRI 1, Marco DI FRAIA 1, Gemma CARO 1, Maria C. FORTUNA 1, Marco PIACENTINI 2, Leonardo CELLENO 3

1 Unit of Dermatology, Sapienza University, Rome, Italy; 2 Eurofins Cosmetics & Personal Care, Rome, Italy; 3 Sacred Heart Catholic University, Rome, Italy


PDF


BACKGROUND: Androgenetic alopecia (AGA) is the most frequent form of alopecia. Telogen effluvium (TE) is a common form of diffuse hair loss mainly observed in women. The aim of our study was to evaluate the efficacy of a topical trichological treatment containing a new combination of molecules for the treatment of AGA and TE.
METHODS: In-vitro tests were performed analyzing different combinations and concentrations of arginine, zinc and a third enzymatically neutral substance called AA on human follicles dermal papillae cells. These tests evaluated the capability of inhibiting the 5α-reductase (5-AR) enzyme and the 5-AR gene expression. We also performed an in-vivo study. Forty individuals affected by AGA and TE were divided into two groups. One group was administered a combination of zinc and arginine (lotion A), whilst the other placebo (lotion B). Therapy duration was 23 consecutive weeks. Follow-up examinations and pull tests occurred at baseline, after 6 weeks and at the end of the therapy. On 20 randomly selected patients we also performed noninvasive phototrichograms.
RESULTS: In-vitro tests showed that the combination had a strong statistically significant inhibitory activity on 5-AR of dermal papillae cells. Number of hairs removed by pull-test significantly decreased at T0, T1 and T2 in patient treated with lotion A. We also observed an increase in the percentage of anagen hair and a decrease in telogen hairs. Concerning phototrichograms, all objective parameters evaluated showed better results in the lotion A group when compared with the placebo group.
CONCLUSIONS: Based on our results, the combination of arginine and zinc tested in our study could represent a good therapeutic option for the treatment of AGA and TE and it might represent a valid alternative to finasteride.


KEY WORDS: Alopecia; Therapeutics; Arginine; Zinc

top of page